Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Ebullient Evolution

Thu, 29th Oct 2009 08:23
Investment management firm Evolution Group expects to beat full year profit forecasts this year on the back of strong trading across all of its divisions.Revenues from the Investment Banking arm in the second half of 2009 will be at least double those seen in the first half, reflecting the increased corporate activity.The company is responding to this increased activity by boosting the division's headcount by around 10% in the second half of the year.On the Private Client Investment Management side, profits continue to pile up, while funds under management hit a record level of £5bn at the end of September, up from £4.2bn at the end of June. Net fund inflows exceeded £100m in the third quarter.'Given the successful results to date from investments made over the last 12 months and our growing business pipeline, the group is highly confident that it can continue the momentum in profit growth into 2010 and beyond,' the company said.

Related News

TRADING UPDATES: Norcros sells Johnson Tiles UK; Trifast trading well
25 Apr 2024

TRADING UPDATES: Norcros sells Johnson Tiles UK; Trifast trading well

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

TRADING UPDATES: Northcoders launches bootcamp; Schroder invests
4 Apr 2024

TRADING UPDATES: Northcoders launches bootcamp; Schroder invests

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

EARNINGS AND TRADING: Ten Lifestyle sees profit up but sales flat
19 Mar 2024

EARNINGS AND TRADING: Ten Lifestyle sees profit up but sales flat

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reporte...

EVG.L News

Evgen Pharma Receives Last Patient For Stroke Treatment Drug Trial
28 Aug 2019

Evgen Pharma Receives Last Patient For Stroke Treatment Drug Trial

(Alliance News) - Evgen Pharma PLC said Wednesday it has entered its last patient in the double-blind, placebo-controlled SAS Phase II clinical trial ...

Evgen Pharma Gets European Patent Covering Composition Of SFX-01
7 Aug 2019

Evgen Pharma Gets European Patent Covering Composition Of SFX-01

(Alliance News) - Evgen Pharma PLC on Wednesday said it has secured further intellectual property rights in Europe for SFX-01.The drug development com...

Evgen Pharma To Collaborate With King's College And British Heart
5 Aug 2019

Evgen Pharma To Collaborate With King's College And British Heart

(Alliance News) - Evgen Pharma PLC said Monday that it backs the new research collaboration between King's College London and the British Heart Founda...

Evgen Pharma Outlook Confident As Progresses Programmes Development
18 Jul 2019

Evgen Pharma Outlook Confident As Progresses Programmes Development

(Alliance News) - Evgen Pharma PLC on Thursday expressed confidence for the year ahead as it continued to progress on the development of its clinical ...

Evgen Pharma Annual Loss Fractionally Wider On Small Expense Rise
13 Jun 2019

Evgen Pharma Annual Loss Fractionally Wider On Small Expense Rise

(Alliance News) - Evgen Pharma PLC on Thursday said its loss marginally widened in its most recent financial year due to slightly higher expenses as d...

Evgen Pharma losses edge wider on higher costs
13 Jun 2019

Evgen Pharma losses edge wider on higher costs

(Sharecast News) - Evgen Pharma on Thursday reported a slightly widened annual loss due to a cost increase, with its results in line with expectations...

Evgen Pharma Raises GBP5 Million Via Share Placing (ALLISS)
17 Apr 2019

Evgen Pharma Raises GBP5 Million Via Share Placing (ALLISS)

LONDON (Alliance News) - Evgen Pharma PLC said Wednesday it raised GBP5.0 million via issue of shares in an oversubscribed placing.The clinical stage ...

Good Headline Results From Evgen Pharma Breast Cancer Study Of SFX-01
25 Mar 2019

Good Headline Results From Evgen Pharma Breast Cancer Study Of SFX-01

LONDON (Alliance News) - Evgen Pharma PLC on Monday announced positive headline results from its phase two Stem trial of SFX-01 in advanced breast can...